Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) insider Martin J. Driscoll acquired 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The stock was bought at an average price of $7.34 per share, for a total transaction of $73,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Spring Bank Pharmaceuticals stock opened at $6.92 on Friday. The stock has a market cap of $116.42 million, a PE ratio of -3.70 and a beta of 0.53. Spring Bank Pharmaceuticals Inc has a 1 year low of $6.30 and a 1 year high of $15.00.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Monday, April 29th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.20. Equities research analysts predict that Spring Bank Pharmaceuticals Inc will post -2.27 earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on SBPH shares. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Cantor Fitzgerald set a $29.00 price target on shares of Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th. Chardan Capital set a $25.00 price objective on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 12th. Finally, Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, May 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Spring Bank Pharmaceuticals has an average rating of “Buy” and an average price target of $23.80.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Recommended Story: P/E Growth (PEG)
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.